Search

Your search keyword '"Plà, María Jesús"' showing total 10 results
Start Over Author "Plà, María Jesús" Publication Type Academic Journals
10 results on '"Plà, María Jesús"'

4. The Shift From Sentinel Lymph Node Biopsy Performed Either Before or After Neoadjuvant Systemic Therapy in the Clinical Negative Nodes of Breast Cancer Patients. Results, and the Advantages and Disadvantages of Both Procedures

Author

Fernandez-Gonzalez, Sergi, Falo, Catalina, Pla, Maria Jesus, Pernas, Sonia, Bajen, Maite, Soler, Teresa, Ortega, Raul, Quetglas, Cecilia, Perez-Martin, Xavier, Fernandez Montoli, Maria Eulalia, Campos, Miriam, Varela-Rodriguez, Mar, Ponce, Jordi, and Garcia-Tejedor, Amparo

Published
2018
Full Text
View/download PDF

7. Study of breast cancer incidence in patients of lymphangioleiomyomatosis

Author

Nuñez, Olivier, Román, Antonio, Johnson, Simon R., Inoue, Yoshikazu, Hirose, Masaki, Casanova, Álvaro, de Garibay, Gorka Ruiz, Herranz, Carmen, Bueno-Moreno, Gema, Boni, Jacopo, Mateo, Francesca, Petit, Anna, Climent, Fina, Soler, Teresa, Vidal, August, Sánchez-Mut, José Vicente, Esteller, Manel, López, José Ignacio, García, Nadia, Gumà, Anna, Ortega, Raúl, Plà, María Jesús, Campos, Miriam, Ansótegui, Emilio, Molina-Molina, María, Valenzuela, Claudia, Ussetti, Piedad, Laporta, Rosalía, Ancochea, Julio, Xaubet, Antoni, Pollán, Marina, and Pujana, Miguel Angel

Published
2016
Full Text
View/download PDF

9. Correction: Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell Stemness.

Author

Ruiz de Garibay G, Herranz C, Llorente A, Boni J, Serra-Musach J, Mateo F, Aguilar H, Gómez-Baldó L, Petit A, Vidal A, Climent F, Hernández-Losa J, Cordero Á, González-Suárez E, Sánchez-Mut JV, Esteller M, Llatjós R, Varela M, López JI, García N, Extremera AI, Gumà A, Ortega R, Plà MJ, Fernández A, Pernas S, Falo C, Morilla I, Campos M, Gil M, Román A, Molina-Molina M, Ussetti P, Laporta R, Valenzuela C, Ancochea J, Xaubet A, Casanova Á, and Pujana MA

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0132546.].

Published
2018
Full Text
View/download PDF

10. Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell Stemness.

Author

Ruiz de Garibay G, Herranz C, Llorente A, Boni J, Serra-Musach J, Mateo F, Aguilar H, Gómez-Baldó L, Petit A, Vidal A, Climent F, Hernández-Losa J, Cordero Á, González-Suárez E, Sánchez-Mut JV, Esteller M, Llatjós R, Varela M, López JI, García N, Extremera AI, Gumà A, Ortega R, Plà MJ, Fernández A, Pernas S, Falo C, Morilla I, Campos M, Gil M, Román A, Molina-Molina M, Ussetti P, Laporta R, Valenzuela C, Ancochea J, Xaubet A, Casanova Á, and Pujana MA

Subjects
Breast Neoplasms genetics, Breast Neoplasms pathology, Gene Expression Profiling, Humans, Lung Neoplasms secondary, Lymphangioleiomyomatosis pathology, Neoplasm Metastasis, Tuberous Sclerosis Complex 1 Protein, Tuberous Sclerosis Complex 2 Protein, Tumor Suppressor Proteins genetics, Biomarkers, Tumor blood, Breast Neoplasms blood, Lung Neoplasms blood, Lymphangioleiomyomatosis blood, Neoplastic Stem Cells pathology
Abstract

Lymphangioleiomyomatosis (LAM) is a rare lung-metastasizing neoplasm caused by the proliferation of smooth muscle-like cells that commonly carry loss-of-function mutations in either the tuberous sclerosis complex 1 or 2 (TSC1 or TSC2) genes. While allosteric inhibition of the mechanistic target of rapamycin (mTOR) has shown substantial clinical benefit, complementary therapies are required to improve response and/or to treat specific patients. However, there is a lack of LAM biomarkers that could potentially be used to monitor the disease and to develop other targeted therapies. We hypothesized that the mediators of cancer metastasis to lung, particularly in breast cancer, also play a relevant role in LAM. Analyses across independent breast cancer datasets revealed associations between low TSC1/2 expression, altered mTOR complex 1 (mTORC1) pathway signaling, and metastasis to lung. Subsequently, immunohistochemical analyses of 23 LAM lesions revealed positivity in all cases for the lung metastasis mediators fascin 1 (FSCN1) and inhibitor of DNA binding 1 (ID1). Moreover, assessment of breast cancer stem or luminal progenitor cell biomarkers showed positivity in most LAM tissue for the aldehyde dehydrogenase 1 (ALDH1), integrin-ß3 (ITGB3/CD61), and/or the sex-determining region Y-box 9 (SOX9) proteins. The immunohistochemical analyses also provided evidence of heterogeneity between and within LAM cases. The analysis of Tsc2-deficient cells revealed relative over-expression of FSCN1 and ID1; however, Tsc2-deficient cells did not show higher sensitivity to ID1-based cancer inhibitors. Collectively, the results of this study reveal novel LAM biomarkers linked to breast cancer metastasis to lung and to cell stemness, which in turn might guide the assessment of additional or complementary therapeutic opportunities for LAM.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results